OBJECTIVE: To evaluate the safety and efficacy of remifentanil-propofol and remifentanil-midazolam analgesia for choledochofiberscopic dilatation of bile duct. METHODS: 95 patients undergoing choledochofiberscopic dilatation of bile duct were reviewed, 43 of which were dealt with remifentanil-propofol (PR) and 52 with remifentanil-midazolam (MR). After medication, changes of HR, MAP, RR and SPO(2) were observed. The effects of sedation and analgesia, the instance of amnesia, and side effects were recorded. RESULTS: HR in group PR and MR were increase at 10 to 20 min and 20 min respectively after medication. MAP in group PR was increased at 20 min, which were decreased in group MR (P < 0.05). Compared with group PR, group MR achieved similar analgesia (P > 0.05), more moderate sedation with modified OAA/S score of 3 - 4 (67% vs 28%, P < 0.01), less memory, less injection pain, and higher satisfaction (P < 0.05). CONCLUSION: Both remifentanil-propofol and remifentanil-midazolam can provide safe and effective sedation and analgesia for choledochofiberscopic dilatation of bile duct. Remifentanil-midazolam provides more stable hemodynamics, more amnesia, moderate sedation duration and less side effects.
OBJECTIVE: To evaluate the safety and efficacy of remifentanil-propofol and remifentanil-midazolam analgesia for choledochofiberscopic dilatation of bile duct. METHODS: 95 patients undergoing choledochofiberscopic dilatation of bile duct were reviewed, 43 of which were dealt with remifentanil-propofol (PR) and 52 with remifentanil-midazolam (MR). After medication, changes of HR, MAP, RR and SPO(2) were observed. The effects of sedation and analgesia, the instance of amnesia, and side effects were recorded. RESULTS: HR in group PR and MR were increase at 10 to 20 min and 20 min respectively after medication. MAP in group PR was increased at 20 min, which were decreased in group MR (P < 0.05). Compared with group PR, group MR achieved similar analgesia (P > 0.05), more moderate sedation with modified OAA/S score of 3 - 4 (67% vs 28%, P < 0.01), less memory, less injection pain, and higher satisfaction (P < 0.05). CONCLUSION: Both remifentanil-propofol and remifentanil-midazolam can provide safe and effective sedation and analgesia for choledochofiberscopic dilatation of bile duct. Remifentanil-midazolam provides more stable hemodynamics, more amnesia, moderate sedation duration and less side effects.